Will ATAI disclose at least 50% enrollment in one or both BPL-003 Phase 3 pivotal trials by 2026-12-31?

Three compounding filters: (1) P(Phase 3 FPD by Q3 2026) ~65% per separate market, (2) P(enrollment reaches 50% of target within 3-6 months of FPD) ~25-30% (typical 8-12 month pace), (3) P(management quantifies the 50% milestone by year-end in a qualifying disclosure) ~45-55%. Joint 0.65 x 0.28 x 0.50 = 0.091. However, I should model the conjunction less conservatively — if 50% is reached, disclosure is often coincident with a press release, raising the quantified-disclosure probability. Adjust P(3|2) upward to 0.60. Joint 0.65 x 0.28 x 0.60 = 0.109. Round up for favorable program factors (strong site infrastructure, single-asset focus): 0.22. Still this is a stretched milestone and below 50/50.

More conservative. Phase 3 TRD trial enrollment pace benchmarks (Janssen Spravato Phase 3: 18 months from FPD to LPD with ~60 sites and non-controlled-substance logistics; ATAI will be slower per site given DEA Schedule I friction). 50% enrollment in 6-8 months requires ~3x the Phase 2b velocity AND exceptional site activation. Even with $256M liquidity and Breakthrough status, operationally this is a stretched milestone. Probability of hitting AND quantifying publicly by 2026-12-31: 0.18.

Slightly higher. ATAI's Phase 2b completed 196 patients across 38 sites in 6 countries — that infrastructure can be reactivated quickly for Phase 3. If 50% of target is 350 patients (for 700-patient aggregate across two trials, or 175 per trial if 350 each), enrollment velocity needed is ~50-60 patients/month across the network. That's within achievable range for a well-resourced Breakthrough program. The quantified-disclosure probability is the softer filter — management may choose to guide qualitatively to preserve flexibility. 0.25.

Three-filter decomposition: FPD by Q3 2026 ~65%, 50% enrollment within 3-6 months ~30%, quantified disclosure ~55%. Joint 0.65 x 0.30 x 0.55 = 0.107. Adjust up for program tailwinds to 0.22. The disclosure filter is material because many biotechs guide qualitatively until full enrollment.

Conservative. Biotech enrollment pace is chronically over-promised. Even with Breakthrough and strong Phase 2b infrastructure, 50% within 6-8 months of FPD is at the fast end of achievable outcomes. Management's default disclosure posture is qualitative. 0.20.

Balanced. If ATAI hits FPD on time AND runs at Phase 2b-proven velocity across a similar site base, 50% is reachable by year-end. Single trial (not both) makes it more achievable. Disclosure is the stretch filter. 0.24.

Enrollment pace 65-75% to reach 50% within 8-12 months of FPD. With 6-8 month window and quantified disclosure filter, probability approximately 0.20.

Single-trial criterion helps, window is tight, disclosure is stretch filter. 0.22.

Mid-range. Multi-filter joint probability compressed by disclosure practice. 0.21.